ACADIA Pharmaceuticals Inc.
US ˙ NasdaqGS ˙ US0042251084

Introduction

This page provides a comprehensive analysis of the known insider trading history of Yang Michael J.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Yang Michael J. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IONS / Ionis Pharmaceuticals, Inc. Director 6,010
US:PCRX / Pacira BioSciences, Inc. Director 13,393
US:ACAD / ACADIA Pharmaceuticals Inc. EVP and CCO 8,167
Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Yang Michael J.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACAD / ACADIA Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACAD / ACADIA Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACAD / ACADIA Pharmaceuticals Inc. Insider Trades
Insider Sales ACAD / ACADIA Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACAD / ACADIA Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-01-06 ACAD YANG MICHAEL J. 1,120 53.3400 1,120 53.3400 59,741 251 15.78 -42,066 -70.42
2020-10-16 ACAD YANG MICHAEL J. 1,247 42.5600 1,247 42.5600 53,072
2020-04-30 ACAD YANG MICHAEL J. 1,501 49.2100 1,501 49.2100 73,864
2019-10-15 ACAD YANG MICHAEL J. 877 39.6500 877 39.6500 34,773

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACAD / ACADIA Pharmaceuticals Inc. Insider Trades
Insider Purchases IONS / Ionis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACAD / ACADIA Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IONS / Ionis Pharmaceuticals, Inc. Insider Trades
Insider Sales IONS / Ionis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACAD / ACADIA Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IONS / Ionis Pharmaceuticals, Inc. Insider Trades
Insider Purchases PCRX / Pacira BioSciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACAD / ACADIA Pharmaceuticals Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-14 PCRX YANG MICHAEL J. 2,000 12.9000 2,000 12.9000 25,800 181 27.2500 28,700 111.24

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Sales PCRX / Pacira BioSciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACAD / ACADIA Pharmaceuticals Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Yang Michael J. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-17 2025-07-15 4 IONS IONIS PHARMACEUTICALS INC
Common Stock
M - Exercise 4,079 6,010 211.24
2025-06-13 2025-06-11 4 PCRX Pacira BioSciences, Inc.
Common Stock
A - Award 6,163 13,393 85.24
2025-01-17 2025-01-15 4 IONS IONIS PHARMACEUTICALS INC
Common Stock
M - Exercise 1,931 1,931
2024-08-14 2024-08-14 4 PCRX Pacira BioSciences, Inc.
Common Stock
P - Purchase 2,000 7,230 38.24 12.90 25,800 93,267
2024-06-13 2024-06-12 4 PCRX Pacira BioSciences, Inc.
Common Stock
A - Award 5,230 5,230
2021-01-08 2021-01-06 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -2,722 8,167 -25.00
2021-01-08 2021-01-06 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -1,120 8,059 -12.20 53.34 -59,741 429,867
2021-01-08 2021-01-06 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 2,722 9,179 42.16
2020-10-19 2020-10-16 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -1,247 6,457 -16.19 42.56 -53,072 274,810
2020-10-19 2020-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -2,500 5,000 -33.33
2020-10-19 2020-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 2,500 7,704 48.04
2020-10-13 2020-10-12 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
D - Sale to Issuer -26,400 0 -100.00 2.01 -53,064
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -14,750 44,292 -24.98
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -5,000 25,000 -16.67
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -7,500 570,000 -1.30
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -11,100 5,204 -68.08 56.54 -627,574 294,225
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -16,150 16,304 -49.76 56.05 -905,212 913,844
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 14,750 32,454 83.31 25.12 370,520 815,244
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 5,000 17,704 39.36 21.28 106,400 376,741
2020-07-09 2020-07-07 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 7,500 12,704 144.12 19.98 149,850 253,826
2020-05-01 2020-04-30 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -1,501 5,204 -22.39 49.21 -73,864 256,089
2020-05-01 2020-04-29 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -4,206 12,621 -25.00
2020-05-01 2020-04-29 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 4,206 6,705 168.31
2020-04-15 2020-04-13 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 26,400 26,400
2020-01-08 2020-01-06 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 10,889 10,889
2020-01-08 2020-01-06 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 39,516 39,516
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -72,979 312,500 -18.93
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -10,000 30,000 -25.00
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -22,500 577,500 -3.75
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -5,032 2,499 -66.82 43.74 -220,075 109,294
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -100,447 7,531 -93.03 44.49 -4,469,188 335,077
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 72,979 107,978 208.52 35.86 2,617,027 3,872,091
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 10,000 34,999 40.00 21.28 212,800 744,779
2019-12-13 2019-12-12 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 22,500 24,999 900.36 19.98 449,550 499,480
2019-12-11 2019-12-09 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -14,521 385,479 -3.63
2019-12-11 2019-12-09 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -3,502 1,623 -68.33 50.05 -175,286 81,236
2019-12-11 2019-12-09 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale X -11,019 5,125 -68.25 50.60 -557,506 259,299
2019-12-11 2019-12-09 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 14,521 16,144 894.70 35.86 520,723 578,924
2019-10-17 2019-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -2,500 7,500 -25.00
2019-10-17 2019-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
S - Sale -877 1,623 -35.08 39.65 -34,773 64,352
2019-10-17 2019-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Common Stock
M - Exercise 2,500 2,500
2019-09-23 2019-09-20 4 AKCA AKCEA THERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 53,000 53,000
2019-05-01 2019-04-29 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 16,827 16,827
2019-05-01 2019-04-29 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 59,042 59,042
2018-10-24 2018-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Restricted Stock Units
A - Award 10,000 10,000
2018-10-24 2018-10-15 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 40,000 40,000
2018-04-20 2018-04-18 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 60,000 60,000
2017-09-08 2017-09-07 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 93,750 93,750
2017-03-31 2017-03-29 4 ACAD ACADIA PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 400,000 400,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)